A call informs Sarah Nealle her six-year-old daughter was in a school bus accident.
Her journey includes: Doctors. An epidural hematoma. Respirators. Apnea tests. Nationwide publicity. Political, moral, ethical, legal, social battles regarding organ transplantation. A family with disagreements.
The lonely decision: how to let her daughter die with dignity. Find out more at http://garybshelly.com/ Literary
Lupe Maldonado will tell you, “education is key.” That’s because it’s what helped her and her family create a brighter future. Their story started in a garage in Torrance, Calif., more than 20 years ago. That’s where they lived when they came to the U.S. No bathroom. No running water; a mattress on the bare floor. They covered up the holes to keep out the cold and the mice. While it may have been a bleak start, Lupe says just being in America was a dream come true.
While Ismael worked 12 hour days to support his family, Lupe joined a new program at her son’s elementary school called the Toyota Family Literacy Program in order to learn English. It was a tough decision, going to school instead of getting a job that could provide the money needed to move out of that garage; but Ismael and Lupe knew if she could learn English, she could advocate for their boys with teachers, doctors and in the community. Ismael also enrolled in English classes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7946551-ncfl-toyota-partnership/
Orbis, the international nonprofit that unites the world in the fight against blindness, is proud to land its new, state-of-the-art Flying Eye Hospital in Shenyang, China this week to commence its first training program, running from September 5 - 23. Six years in the making, the third-generation Flying Eye Hospital is the world’s only mobile ophthalmic teaching hospital on board an MD-10 aircraft, donated by FedEx. Hundreds of experts have come together to combine the latest in avionics, hospital engineering, technology and clinical expertise to make the new Flying Eye Hospital a reality. It features modular design, 3D technology and live broadcast capabilities, which enables Orbis and their expert Volunteer Faculty to train more doctors, nurses and healthcare professionals—ultimately treating more people and restoring their sight.
“Today, I am incredibly proud that our Flying Eye Hospital can get to work on its first program,” Bob Ranck, Orbis CEO and President, said. “It is a testament to the hundreds of volunteers, global corporate partners, governments and other individuals who have worked tirelessly to make this unique aircraft a reality, and we thank them one and all. Our mission at Orbis is to bring the world together to fight blindness, and the Flying Eye Hospital is an important tool for achieving this. It is an equal-parts teacher, envoy and advocate for the right to sight. We are excited to start this new chapter in Orbis history here in Shenyang, China.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7316251-orbis-flying-eye-hospital/
Today, WebMD released Path to a Breakthrough, a five-part original video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, Path to a Breakthrough sheds light on how medical innovations, including Precision Medicine, Immunotherapy, and Biologics, are providing doctors with powerful new tools to treat disease, alleviate symptoms, and in some cases, reverse the course of debilitating illness.
In this extraordinary new series, WebMD and Roberts share the stories of Cara, a 4-year-old girl who lost, then regained her ability to walk from the clues hidden in her genetic makeup; Trevor, a man diagnosed with stage IV Lymphoma in the prime of his life, and the doctor who helped him harness his own immune system for a nontoxic cancer treatment; Kevin, whose pain from dirt bike racing injuries was nothing compared to the excruciating pain of Rheumatoid Arthritis; Falisha, whose life-changing diagnosis of Multiple Sclerosis was alleviated by biologics; and Rebecca, whose debilitating Psoriasis led to blindness.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579754-webmd-path-to-a-breakthrough/
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world. CLS has a stream of innovative product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV).
CLS’s new digital presence demonstrates the company’s intent to change the way that customers think about a valued dermatology partner. CLS believes that it can make an impact in the current state of dermatology practice through its commitment to focus on unmet and underserved patient needs. In turn this will help medical professionals optimize their practice time through CLS products and services.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743651-cutanea-life-sciences-dermatology/
The Council of Community Clinics (CCC), a premier consortium of primary care organizations in Southern California, today announced its new name and branding, Health Center Partners, the new name for its subsidiary formerly known as Community Clinic Health Network, Health Quality Partners, and the launch of Integrated Health Partners. Integrated Health Partners is a fully integrated primary health network designed to advance standards of care, improve outcomes and reduce costs for member community health centers. On the heels of its recently augmented executive leadership team and the addition of new member Community Health Systems, Inc., Health Center Partners today unveiled its innovative vision for meeting the evolving health needs of nearly 800,000 low-income and uninsured Californians at a launch ceremony in San Diego.
To view the multimedia release go to:
http://www.multivu.com/players/English/7774351-health-center-partners-unveils-community-health-vision/
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7562351-lung-care-asthma-mobile-app/
Long before it's time for hospice care, many people with serious illness can benefit from palliative care but don’t realize it. Sometimes referred to as “comfort care,” palliative care is a specialized approach to the treatment of patients with a serious or life-threatening illness. Palliative care has helped Deadra Gladden get her life back through symptom management and support from Samaritan Healthcare & Hospice, Marlton, N.J.
In May of 2014 Deadra, age 28, was in the hospital, feeling hopeless and in excruciating pain due to lupus, a disease she has been battling for over half her young life. Deadra's doctors told her family it was time to call hospice. But after consulting with a nurse from Samaritan Healthcare and Hospice, a palliative care team was brought in instead.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer.
Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
